Equity Research, Broker Reports, and media content on Summit Therapeutics

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Summit Therapeutics
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Summit Therapeutics. We currently have 109 research reports from 3 professional analysts.

Open
23.8p
Range Today
22.5/23.9p
52 Week
17.5/32.5p
Daily Volume
22.5k
# Shares
160.5m
Daily Liquidity
(0.01%)
Pension Liability
£0m
Enterprise Value
£8.29m
Market Cap
£38.1m
Latest PE (hist)
2.38
Div Yield
Date Source Announcement
06Nov19 12:00 GNW Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
04Nov19 12:00 GNW Summit Therapeutics Recognises C. difficile Awareness Month
16Oct19 12:00 GNW Summit Therapeutics to Present at the 2019 BIO Investor Forum
11Oct19 12:01 GNW Directorate change
11Oct19 12:00 GNW Half-year report
10Oct19 14:30 GNW Notice of Results
07Oct19 12:00 GNW Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
  • Frequency of research reports

     

  • Research reports on

    Summit Therapeutics

  • Providers covering

    Summit Therapeutics